This company listing is no longer active
NMTR Stock Overview
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
9 Meters Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$6.56 |
| 52 Week Low | US$0.18 |
| Beta | 1.48 |
| 1 Month Change | -72.75% |
| 3 Month Change | -85.45% |
| 1 Year Change | -96.00% |
| 3 Year Change | -98.32% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
9 Meters Biopharma to execute 1-for-20 reverse stock split
Oct 179 Meters Biopharma GAAP EPS of -$0.04 in-line
Aug 159 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome
Jun 149 Meters drug effective in treating rare COVID-19 complication in children
May 269 Meters Bio gains 5% on Adage Capital stake disclosure
Dec 299 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications
Dec 219 Meters Bio launches equity offering
Dec 11Shareholder Returns
| NMTR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -71.1% | -3.0% | 3.2% |
| 1Y | -96.0% | 0.8% | 24.0% |
Return vs Industry: NMTR underperformed the US Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: NMTR underperformed the US Market which returned 16.1% over the past year.
Price Volatility
| NMTR volatility | |
|---|---|
| NMTR Average Weekly Movement | 22.4% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NMTR's share price has been volatile over the past 3 months.
Volatility Over Time: NMTR's weekly volatility has increased from 17% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 10 | Bethany Sensenig | www.9meters.com |
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease.
9 Meters Biopharma, Inc. Fundamentals Summary
| NMTR fundamental statistics | |
|---|---|
| Market cap | US$2.82m |
| Earnings (TTM) | -US$46.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs NMTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMTR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$46.28m |
| Earnings | -US$46.28m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -80.5% |
How did NMTR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/18 12:46 |
| End of Day Share Price | 2023/07/18 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
9 Meters Biopharma, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Jonathan Aschoff | B. Riley Wealth |